# Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)

> **NCT04110275** · PHASE2 · UNKNOWN · sponsor: **Angde Biotech Pharmaceutical Co., Ltd.** · enrollment: 174 (estimated)

## Conditions studied

- Acute Pulmonary Embolism

## Interventions

- **DRUG:** Recombinant human tissue-type plasminogen activator derivative
- **DRUG:** Recombinant human tissue-type plasminogen activator

## Key facts

- **NCT ID:** NCT04110275
- **Lead sponsor:** Angde Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10
- **Primary completion:** 2021-05
- **Final completion:** 2021-08
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2019-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04110275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04110275, "Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04110275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*